Oncology protocols are tighter, the competitive field is denser, and the margin for poor site selection is narrower. Rightview gives oncology teams the protocol, site, and competitive data to make those calls with actual evidence.
Oncology trials have some of the tightest eligibility criteria, most complex multi-arm designs, and highest screen failure rates in the industry. Rightview benchmarks thousands of oncology protocols so you know what actually works before you finalize yours.
Checkpoint inhibitors, CAR-T, ADCs, combination therapies: hundreds of sponsors competing in the same space. Track competitor protocols, enrollment activity, and new drug signals across every modality in your indication.
Cancer centers vary widely in trial experience, tumor board infrastructure, and therapeutic focus. Rightview matches sites to your indication and protocol parameters, so you know which sites have the patient population and bandwidth before you make first contact.
In oncology, the right principal investigator can determine whether a trial enrolls on time. Map KOL networks, understand investigator specialization by tumor type, and identify top-performing PIs before your CRO hands you a list.
Deep-dive analyses on oncology trial trends, competitive landscapes, and protocol benchmarks published by the Rightview research team.
Analysis of checkpoint inhibitor trial design trends, enrollment patterns, and competitive dynamics across PD-1/PD-L1 programs.
Site performance data across major oncology indications, including activation timelines, enrollment rates, and investigator experience metrics.
How oncology protocol complexity has evolved over the past decade visit burden, I/E criteria inflation, endpoint proliferation, and more.
Tell us about your indication. We'll show you what the data says about your competitive landscape, the best-matched sites, and how similar protocols are designed.
Schedule a Demo